(I-BusinessNews.Com, July 08, 2021 ) Companies in the rituximab biosimilar market are increasing their product innovation and marketing activities through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in- or out-licensing deals, this trend has been increasing over recent years. For instance, In October 2019, iBio, Inc., Delware-based biotechnology company involved in development of vaccine and therapeutics expanded its strategic partnership/collaboration with CC-Pharming, a Beijing-based company specialized in biological R&D for development of rituximab biosimilar in China.
The rituximab biosimilars market consists of sales of rituximab biosimilars. Biosimilars are pharmaceuticals that are manufactured using cell lines and are similar to biologics. Rituximab biosimilars are used as a single agent or in combination with chemotherapy for the treatment of various diseases including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), microscopic polyangiitis (MPA), and granulomatosis with polyangiitis (GPA).
Rituximab Biosimilars Market Report Segments:
1) By Application: Non-Hodgkin’s Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis, Others
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels
3) By Route Of Administration: Subcutaneous, Intravenous, Molecular Type
Read More On The Global Rituximab Biosimilars Market Report:
Rituximab Biosimilars Market Size Forecast:
The global rituximab biosimilars market is expected to grow from $1.75 billion in 2020 to $1.9 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The rituximab biosimilars market is expected to reach $3.02 billion in 2025 at a CAGR of 12%.
Major Players in the Rituximab Biosimilars Market:
Teva Pharmaceutical Industries Ltd.
Celltrion Healthcare Co. Ltd.
Request For A Sample:
Rituximab Biosimilars Market – Opportunities And Strategies Â Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provide market overviews, analyze and forecast market size and growth for the whole market, rituximab biosimilars market segments and geographies, rituximab biosimilars market trends, drivers, restraints, leading competitorsÂ revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies.
The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitorsÂ approaches.
Here Is A List Of Reports Similar To The Rituximab Biosimilars Global Market Report By The Business Research Company:
CAR-T Therapy Market – By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies – Global Forecast To 2030
Oncology Drugs Market – By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Kidney Cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid Cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies – Global Forecast To 2030
Dry Eye Medication Market – By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies) By Delivery System (Liquid, Gel, Ointment, Others) And By Region, Opportunities And Strategies Â Global Forecast To 2030
Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
The Business Research Company